MariMed to Exhibit Florance™ at Natural Products Expo East on September 11-14, 2019
NORWOOD, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- MariMed Inc. (OTCQX: MRMD), a premier cannabis and hemp multi-state operator focused on health and wellness, announced today its MariMed Hemp division will exhibit its Florance™ brand of CBD products at Natural Products Expo East being held at the Baltimore Convention Center on September 11-14, 2019.
The expo will bring together more than 27,000 attendees including brands, buyers, investors, entrepreneurs and industry experts in the health, wellness and eco-conscious community.
The Florance brand is sold in the U.S. and EU through online distributors, wholesalers, pharmacies and physicians. MariMed invites attendees to stop by the company’s booth #4902 where it will exhibit its full line of Florance Hemp CBD products in several categories, including health, beauty, pain and sports.
Dr. Jokūbas Žiburkus, MariMed’s chief innovation officer and one of the founders of the Florance brand, has organized an experienced medical team to develop new formulations that produce consistent and satisfying results for consumers and patients.
Following its investment in GenCanna Global, the Kentucky-based leader in production of GMP quality CBD derived from hemp, MariMed formed MariMed Hemp to build and distribute a portfolio of innovative CBD brands and pursue business opportunities in the emerging hemp and CBD industry.
About MariMed Inc.
MariMed Inc., a multi-state cannabis operator, is dedicated to improving the health and wellness of people through the use of cannabinoids and cannabis products. The company develops, owns and manages seed to sale state licensed cannabis facilities which are models of excellence in horticultural principles, cannabis cultivation, cannabis infused products and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the company and its managed business units.
The company is at the forefront of science and innovation through research developed by its lab technicians and medical advisors resulting in industry leading products and brands, including “Kalm Fusion” and “Betty’s Eddies.” These precision dosed products are focused on specific medical symptoms which are licensed and distributed across the country.
In 2019, with the enactment of the 2018 US Farm Bill, MariMed formed MariMed Hemp, a wholly owned subsidiary, to leverage its seed to sale cannabis platform and experience into the emerging hemp-based CBD industry. The company acquired a significant stake in Kentucky-based GenCanna Global, a national and international leading cultivator, producer, and distributer of hemp and GMP quality CBD oils and isolates. With this strategic relationship, MariMed Hemp has developed and is marketing a portfolio of CBD brands and products to multiple retailers and direct to consumers both domestically and internationally. MariMed Hemp recently launched its Hemp Engine™ store-within-a-store distribution platform for retailers. It is also actively pursuing other hemp industry business opportunities with genetics, farming, biomass, and new and innovative technologies.
For additional information, visit marimedinc.com.
Facebook: MariMedInc
Important Caution Regarding Forward Looking Statements
This release contains certain forward-looking statements and information relating to MariMed Inc. that is based on the beliefs of MariMed Inc.’s management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the law and its enforcement and changes in the economic environment. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "planned, "estimated," "preparing," "potential," "expected," “looks” or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.
All trademarks and service marks are the property of their respective owners.
Company Contact
Jon Levine, CFO
MariMed Inc.
Tel (781) 559-8713
Media & Investor Contact
Ronald Both or Jonathan Leuchs
CMA
Tel (949) 432-7566
MRMD@cma.team
Released September 9, 2019